Biotech partner drops GlaxoSmithKline’s adjuvant as it moves Covid-19 vaccine into PhII/III, citing ‘manufacturing considerations’
When GlaxoSmithKline revealed that its Sanofi-partnered recombinant protein-based Covid-19 vaccine program was running into a major delay, the pharma giant tucked in a paragraph …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.